The US Food and Drug Administration has approved a once-weekly insulin treatment for children and adolescents aged 10 years and older with type 2 diabetes, expanding the treatment options available to younger patients. The approval of insulin icodec-abae, marketed as Awiqli, was reported by JAMA on November 20.

A Weekly Alternative To Daily Basal Insulin

Insulin icodec-abae is a long-acting insulin analogue designed to be administered once a week. The medicine had previously been approved for adults earlier in 2026. The paediatric approval means eligible patients aged 10 and above with type 2 diabetes may have an alternative to basal insulin regimens that require daily injections, according to JAMA’s medical news report.

The FDA’s decision was supported by a single-dose study involving 18 paediatric patients. JAMA reported that children absorbed the initial dose more quickly than adults, while absorption after repeated dosing was similar. The agency said the findings suggested comparable glucose-lowering effects with repeated use.

What Patients And Families Should Know

The weekly schedule could reduce the number of injections required for some young patients, but insulin remains a medicine that requires careful clinical supervision. Families and clinicians must consider blood glucose monitoring, dose adjustment, hypoglycaemia risk, meal patterns and other aspects of diabetes management when selecting a treatment.

The reported safety profile was described as consistent with other insulin products. However, the paediatric evidence cited in the JAMA report was based on a small study, and treatment decisions should be made by the child’s diabetes care team using the approved prescribing information.

The approval does not mean every child with type 2 diabetes should switch to weekly insulin. It adds another option for eligible patients and clinicians to consider. The report was published in JAMA on November 20, 2026, with further details available through the journal’s coverage of the FDA decision.